P-1156. In Vitro Antimicrobial Activity of Cefepime in Combination with Taniborbactam Against Resistant Clinical Gram-negative Isolates from a Global Collection, 2018-2023

TL;DR

This study shows that the combination of cefepime and taniborbactam is effective against many drug-resistant Gram-negative bacteria worldwide.

Contribution

The novel combination of cefepime and taniborbactam shows potent activity against resistant Gram-negative isolates.

Findings

FTB inhibited 99.5% of Enterobacterales isolates at ≤16 µg/mL.

FTB inhibited 96.2% of Pseudomonas aeruginosa isolates at ≤16 µg/mL.

FTB was more effective than comparators against multidrug-resistant isolates.

Abstract

Taniborbactam is a novel broad-spectrum β-lactamase inhibitor with inhibitory activity against both serine- and metallo-β-lactamases. Taniborbactam restores the activity of cefepime (FEP) against many difficult to treat organisms, including cephalosporin- and carbapenem-resistant Enterobacterales (EB) and Pseudomonas aeruginosa (PA). The activities of cefepime-taniborbactam (FTB) and comparators were evaluated against nonsusceptible (NS)/resistant (R) clinical isolates of EB and PA collected for the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) program.

MICs of FTB (with taniborbactam fixed at 4 µg/mL) and comparators were determined by broth microdilution (CLSI M07Ed12) against EB (n=23,624) and PA (n=9,427) collected from 351 clinical sites in 62 countries from 2018-2023. For FTB, a provisional susceptible breakpoint of ≤16 µg/mL was used for comparative purposes. NS/R phenotypes were based on 2025 CLSI breakpoints (EUCAST breakpoint for meropenem-vaborbactam [MEV] against PA). Multidrug R (MDR) was defined as R to sentinel agents from ≥3 drug classes.

Similar percentages (15.7%) of EB isolates were R to FEP and piperacillin-tazobactam (TZP), (Table). FTB had potent activity against all EB (MIC90, 0.25 µg/mL; 99.5% inhibited at ≤16 µg/mL). FTB maintained activity against >90% of meropenem (MEM)-NS, and ceftolozane-tazobactam (CT)-R EB, and >80% of MEV- and ceftazidime-avibactam (CZA)-R isolates. FTB at ≤16 µg/mL inhibited 96.6% of EB identified as MDR. FTB was the most active agent against PA overall (MIC90, 8 µg/mL; 96.2% inhibited at ≤16 µg/mL). Among MEM-NS PA isolates, 87.2% were inhibited by FTB at ≤16 µg/mL compared to 61.0% susceptible to CT. FTB at ≤16 µg/mL inhibited 67.9% of CT-R isolates whereas 18.4% and 22.7% of these isolates were susceptible to CZA and MEV, respectively. Against MDR PA (17.4% of all PA), FTB inhibited 78.8% at ≤16 µg/mL compared to 34.5% susceptible to CT.

FTB had potent in vitro activity against worldwide EB and PA, including MDR isolates and isolates R/NS to FEP, TZP, MEM, MEV, CT, and/or CZA. These data support continued development of FTB as a potential treatment option for challenging infections due to resistant Gram-negative pathogens.

Mark G Wise, PhD, IHMA: Employee

Figures